Summary
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Official Title
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies
Keywords
Cancer, Rollover, pan-tumor, Leucovorin, Bevacizumab, Pembrolizumab, Nivolumab, Ipilimumab, Relatlimab, Sunitinib, Capecitabine, Oxaliplatin, Fluorouracil, Pemetrexed, Temozolomide, Daratumumab, Trametinib, Rucaparib, Cabozantinib, Nivolumab + Relatlimab, Regorafinib, Enzalutamide, B1: Nivolumab + Ipilimumab, B2: Nivolumab + Ipilimumab + Cabozantinib, B3: Nivolumab + Ipilimumab + Trametinib, C5: Relatlimab + Nivolumab + Ipilimumab, C6: Relatlimab + Nivolumab + Capecitabine, C9: Relatlimab + Nivolumab SAV + Bevacizumab, D1: Nivolumab + Temozolomide, D2: Nivolumab + Rucaparib, D3: Nivolumab + Daratumumab, D4: Nivolumab + Bevacizumab, E1: Bevacizumab Monotherapy, E2: Regorafinib Monotherapy, E4: Leucovorin + Oxaliplatin + Fluorouracil, E5: Enzalutamide Monotherapy, E6: Sunitinib Monotherapy, E7: Rucaparib Monotherapy, E8: Capecitabine Monotherapy, E9: Cabozantinib Monotherapy, E10: Pemetrexed Monotherapy, E11: Pembrolizumab Monotherapy, E3: Leucovorin + Fluorouracil